Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as EPO906 (patupilone), Patupilone, Epothilone B
EPO906 · 8 trials · 12 indications
Objective tumor response was defined by the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines assessed by radiologic techniques and/or physical examination.
tumor response was defined by the Response Evaluation Criteria in Solid Tumors (RECIST).
| Arm | Type | Description |
|---|---|---|
| Patupilone | EXPERIMENTAL | - |
| doxorubicin | ACTIVE_COMPARATOR | - |
| EPO906 | EXPERIMENTAL | - |
| Bolus | EXPERIMENTAL | 20 min bolus infusion |
| CIV-1d | EXPERIMENTAL | 1 day continuous infusion |
| CIV-5d | EXPERIMENTAL | 5 day continuous infusion |
| Name | Type | Description |
|---|---|---|
| EPO906 (Patupilone) | DRUG | - |
| doxorubicin | DRUG | - |
| epothilone b | DRUG | - |
Inclusion Criteria: * 18 years of age or older * Confirmed diagnosis of ovarian, fallopian or peritoneal cancer * No more than three chemotherapy regimens * Most recent regimen must have been platinum based Exclusion Criteria: * Have an unresolved bowel obstruction * Have had previous chemotherap...
Top 20 of 60 competitors
EPO906 is an investigational oncology drug studied in colon cancer and ovarian cancer. It has been tested in advanced colon cancer and in ovarian, primary fallopian, or peritoneal cancer. It is not described as an approved therapy, and the trials listed for these indications have been completed.
EPO906 is developed by Novartis AG, which trades under the ticker NVS. Novartis is the sponsor associated with the clinical development of the drug in colon cancer and ovarian cancer.
EPO906 has been studied across Phase 1 and Phase 3 clinical development. One Phase 1 dose-escalation trial in advanced colon cancer and one Phase 3 trial in ovarian, primary fallopian, or peritoneal cancer are both listed as completed, and no trials are currently active.
EPO906 has been evaluated in two completed studies. NCT00969046 was a Phase 1 dose-escalation study in advanced colon cancer patients, enrolling 60 participants across Czechia, France, Spain, and the United Kingdom. NCT00262990 was a Phase 3 trial comparing patupilone with doxorubicin in ovarian, primary fallopian, or peritoneal cancer, enrolling 829 female participants.
Yes, EPO906 is also known as patupilone. The two names refer to the same investigational agent, so searches for either name point to the same drug developed by Novartis AG for colon cancer and ovarian cancer.
EPO906 is a small molecule oncology agent, but its specific molecular target is not established here. It has been investigated in controlled clinical trials in advanced colon cancer and in ovarian, primary fallopian, or peritoneal cancer, including a Phase 3 study comparing it with doxorubicin.